NDA 209115 · Pharmaand
Rubraca
Rucaparib Camsylate · Oral
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Dec 19, 2016
Approved uses
8
Original approval plus efficacy supplements
Registered trials
7
1 Phase 3, 0 recruiting
FAERS reports
8,796
3,821 serious, 510 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 16, 2026.
RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. 1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )]. 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a...
Mechanism: Rucaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. In vitro studies have shown that rucaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cancer cell death. Increased rucaparib-induced cytotoxicity and anti-tumor activity was observed in tumor cell lines with deficiencies in BRCA1/2 and other DNA repair genes. Rucaparib has been shown to decrease tumor growth in mouse xenograft models of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 17, 2025 Supplement 15 · Efficacy LetterLabel
- Dec 17, 2025 Supplement 14 · Efficacy LetterLabel
- Dec 21, 2022 Supplement 13 · Efficacy · priority review LetterLabel
- Jun 10, 2022 Supplement 11 · Efficacy · priority review LabelLetter
- Oct 8, 2020 Supplement 8 · Efficacy · priority review LetterLabel
- May 15, 2020 Supplement 4 · Efficacy · priority review Breakthrough therapyLabelLetter
- Apr 6, 2018 Supplement 3 · Efficacy · priority review OrphanLabelLetter
- Dec 19, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
3 products under this application
- RUBRACA · RUCAPARIB CAMSYLATE EQ 250MG BASE · TABLET, ORAL · Prescription
- RUBRACA · RUCAPARIB CAMSYLATE EQ 200MG BASE · TABLET, ORAL · Prescription
- RUBRACA · RUCAPARIB CAMSYLATE EQ 300MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rucaparib Camsylate" as an intervention, any sponsor and status, largest first.
pharmaand GmbHIndustry
NCT04171700 · 83 participants · Start Jan 16, 2020 · Primary completion Jun 8, 2022
Drug: Rucaparib · For: Solid Tumor
Sites: Los Angeles, California; San Francisco, California; Fort Myers, Florida · 19 sites in all
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation TherapyPivotal-lookingActive, not recruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT04455750 · 61 participants · Start Oct 14, 2021 · Primary completion Mar 15, 2027
Drug: Enzalutamide; Rucaparib camsylate and 4 more · For: Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8 and 2 more
Sites: Anchorage, Alaska; Phoenix, Arizona; Hot Springs, Arkansas · 414 sites in all
Ohio State University Comprehensive Cancer CenterAcademic, hospital or other
NCT03552471 · 25 participants · Start Jul 12, 2018 · Primary completion Jun 24, 2022
Drug: Mirvetuximab Soravtansine; Rucaparib Camsylate · For: BRCA1 Gene Mutation; BRCA2 Gene Mutation; Folate Receptor Alpha Positive and 7 more
Sites: Columbus, Ohio
University of WashingtonAcademic, hospital or other
NCT03442556 · 18 participants · Start Aug 24, 2018 · Primary completion Jun 4, 2025
Drug: Carboplatin; Docetaxel and 2 more · For: ATM Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation and 7 more
Sites: Seattle, Washington
pharmaand GmbHIndustry
NCT02740712 · 17 participants · Start Apr 2016 · Primary completion Mar 2017
Drug: Caffeine; Warfarin and 5 more · For: Neoplasms
Sites: Kajetany, Poland; Poznan, Poland; Szczecin, Poland
pharmaand GmbHIndustry
NCT03521037 · 16 participants · Start Feb 27, 2018 · Primary completion Sep 27, 2019
Drug: Rucaparib camsylate · For: Neoplasms
Sites: Biała Podlaska, Poland; Poznan, Poland; Szczecin, Poland · 6 sites in all
pharmaand GmbHIndustry
NCT02986100 · 6 participants · Start Nov 2016 · Primary completion Dec 2017
Drug: C-14 labeled Rucaparib; Rucaparib · For: Solid Tumor
Sites: Budapest, Hungary
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue2,553
- nausea2,263
- malignant neoplasm progression1,184
- decreased appetite802
- diarrhoea790
- constipation785
- vomiting784
- asthenia681
- adverse event571
- carbohydrate antigen 125 increased571
- dysgeusia567
- anaemia557
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2017 | 1,423 |
| 2018 | 1,516 |
| 2019 | 1,834 |
| 2020 | 1,442 |
| 2021 | 1,057 |
| 2022 | 889 |
| 2023 | 183 |
| 2024 | 243 |
| 2025 | 137 |
| 2026 | 70 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rubraca (Rucaparib Camsylate)
2024 spending
$31.5M
Beneficiaries
396
2,278 claims
Per beneficiary
$79,573
$144.47 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $70,706,784 |
| 2021 | $64,385,480 |
| 2022 | $49,037,919 |
| 2023 | $43,036,982 |
| 2024 | $31,510,916 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Pharmaand
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.